CAMBRIDGE, Mass., Dec. 3, 2010 /PRNewswire/ — Sermo (http://www.sermo.com), the world’s
largest online community for physicians, today announced a free
Sermo Report titled, “Potential
Replacements for Coumadin (warfarin).” The report gathered
feedback from physicians about awareness and understanding of these
products and potential barriers to prescribing.
65% of all respondents were aware that a new product, Pradaxa
(dabigatran etexilate mesylate), was currently available for use.
Others indicated that while they may use Pradaxa, they are awaiting
the approval of a similar drug, Xarelto (rivaroxaban).
This free Sermo
Report polled 141 physicians across multiple specialties.
Respondents discussed the importance of understanding how to
reverse the effects of these medications when necessary, drug-drug
interactions and dosing.
Physicians shared their points of view on the advantages of
“…I think that this will be a watershed event in the treatment
of non-valvular AF, and hopefully in other conditions, such as VTE,
requiring anti-coagulation. I hope that soon Coumadin will
only be found in history books”
“Dosing up to twice a day compared to once a day for warfarin
could be acceptable since dabigatran needs no monitoring. Still QD
dosing improves compliance.”
Many of the respondents also participated in an online
discussion regarding various treatment strategies and shared their
plans to use the newly available therapy.
The full report includes:
- Key Findings
- Physician Demographics
- Discussion Highlights
- Quantitative and Qualitative Post Analysis
Companies that are in t